×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NGNE – neurogene inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NGNE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/24
07:39 am
ngne
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates [Yahoo! Finance]
Medium
Report
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates [Yahoo! Finance]
3/24
07:30 am
ngne
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Medium
Report
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
3/11
07:30 am
ngne
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Low
Report
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
3/3
04:11 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/3
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/27
01:33 pm
ngne
Neurogene (NGNE) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $200.00 price target on the stock.
Medium
Report
Neurogene (NGNE) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $200.00 price target on the stock.
2/26
04:14 pm
ngne
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
High
Report
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
2/26
04:01 pm
ngne
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
High
Report
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/24
04:05 pm
ngne
Form 10-K Neurogene Inc. For: Dec 31
Medium
Report
Form 10-K Neurogene Inc. For: Dec 31
3/24
07:31 am
ngne
Form 8-K Neurogene Inc. For: Mar 24
Medium
Report
Form 8-K Neurogene Inc. For: Mar 24
3/17
06:02 pm
ngne
Form 4 Neurogene Inc. For: Mar 13 Filed by: Cobb Stuart
Medium
Report
Form 4 Neurogene Inc. For: Mar 13 Filed by: Cobb Stuart
3/17
06:01 pm
ngne
Form 4 Neurogene Inc. For: Mar 13 Filed by: Cvijic Christine Mikail
Medium
Report
Form 4 Neurogene Inc. For: Mar 13 Filed by: Cvijic Christine Mikail
3/13
04:20 pm
ngne
Form 144 Neurogene Inc. Filed by: Cobb Stuart
Low
Report
Form 144 Neurogene Inc. Filed by: Cobb Stuart
3/3
05:04 pm
ngne
Form 4 Neurogene Inc. For: Feb 27 Filed by: Cvijic Christine Mikail
Medium
Report
Form 4 Neurogene Inc. For: Feb 27 Filed by: Cvijic Christine Mikail
2/27
04:51 pm
ngne
Form 144 Neurogene Inc. Filed by: Cvijic Christine Mikail
High
Report
Form 144 Neurogene Inc. Filed by: Cvijic Christine Mikail
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: